Background
UniProt entry Q16206 encodes a protein implicated in cellular processes relevant to oncogenesis, though its specific role in ovarian carcinoma remains underexplored. Ovarian carcinoma is a heterogeneous malignancy with complex molecular underpinnings, and identifying novel molecular targets is critical for advancing precision oncology. The putative involvement of Q16206 in ovarian carcinoma is suggested by its differential expression patterns observed in multiple transcriptomic datasets, positioning it as a candidate biomarker or therapeutic target warranting further investigation.
Data-mining rationale
This candidate emerged from a systematic cross-referencing of reviewed human UniProt entries annotated for "ovarian carcinoma" against a comprehensive collection of 686 microarray datasets housed in the NCBI Gene Expression Omnibus (GEO). Several GEO datasets (GDS:200333343, GDS:200322784, GDS:200301530, GDS:200319500, GDS:200315735) profiling ovarian carcinoma samples revealed expression signals for Q16206. These datasets collectively suggest a pattern of altered expression associated with ovarian carcinoma, highlighting Q16206 as a putative target identified through integrative bioinformatic reanalysis.
Why prior analyses may have missed this
Many of the original microarray studies predate the widespread adoption of modern empirical-Bayes statistical frameworks, such as the limma package, which incorporates robust multiple-testing correction methods like the Benjamini-Hochberg false discovery rate (FDR). Consequently, earlier analyses may have lacked sufficient statistical power or rigor to detect subtle but biologically meaningful differential expression of Q16206. The absence of registered Phase 1 or later clinical programs targeting Q16206 further suggests that this candidate has not yet been prioritized for translational development, potentially due to limitations in prior data analysis approaches.
Reasoning for further validation
Q16206 warrants experimental validation as a putative target in ovarian carcinoma based on its recurrent expression signals across multiple independent transcriptomic datasets. Re-analysis of the matched GEO datasets using limma with stringent FDR control is essential to confirm statistically significant differential expression. Subsequent validation by quantitative PCR in independent patient cohorts would strengthen evidence for its disease association. Investigating tissue specificity through resources such as GTEx and the Human Protein Atlas can clarify its expression profile in normal versus malignant ovarian tissue. Network analyses using STRING or OmniPath may elucidate its pathway context and potential interactions relevant to tumor biology. If validated, assessment of druggability via databases like DGIdb and ChEMBL could inform early-stage therapeutic targeting strategies. Collectively, these steps will clarify the biological and clinical relevance of Q16206 in ovarian carcinoma and guide future translational research.